Therapy Area topics
And when the long-awaited trial does finally report it will have to be a smash hit.
But with the obvious buyer, Bristol, having apparently been outbid, there might be questions over Acceleron’s takeout price.
Central Nervous System
After the Valor defeat, the group and its partner Biogen will hope that going earlier could improve the amyotrophic lateral sclerosis project’s chances.
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
The stock crashed on Friday as balstilimab’s US filing was pulled – an event that had been entirely foreseeable.
Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.
This month Pliant Therapeutics claimed a win in idiopathic pulmonary fibrosis, but other projects have fallen by the wayside.